Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that enables the detection of pathogens, such as viruses, bacteria, and fungi, as well as genetic mutations through the analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas. Genomtec S.A. was founded in 2016 and is based in Wroclaw, Poland.
Frequently asked questions
What sector does Genomtec S.A. (GMT) operate in?
Genomtec S.A. belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Genomtec S.A. (GMT) current stock price?
As of the latest data, Genomtec S.A. stock price is PLN 3.90, with a previous close of PLN 4.05. Genomtec S.A. lost -PLN 0.15 in the last trading session, representing a -3.58% loss.
What is Genomtec S.A. (GMT) current market capitalization?
Genomtec S.A. market cap is approximately 66.55 million.
What is Genomtec S.A. (GMT) Earnings Per Share (EPS)?
The trailing EPS is -PLN 0.62.
What is Genomtec S.A. (GMT) EBITDA?
Genomtec S.A. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.79 million.
Does Genomtec S.A. (GMT) pay dividends?
No. Genomtec S.A. does not pay a dividend.
What is Genomtec S.A. (GMT) beta (volatility) score?
Genomtec S.A. has a beta of 0.302, indicating lower volatility than the overall market.
